Tag archive for ‘MYL’
Antares: Teva Offer to Buy Mylan Should Have No Effect on Launch of AB Rated Generic to EpiPen (ATRS, $2.76, Buy)
Overview Subsequent to my posting of my recent update on Antares, I have seen that Teva has made an offer to buy Mylan; Mylan, of course, markets EpiPen. My first reaction to this news was alarm suggesting that Teva would abandon the AB rated product and focus on the branded product. However, this is highly […]